Dr. İlyas Şahin Medical Oncologist

Scientific publications

2.900+

citations, Google Scholar (October 2026)

  • Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology, 2024.
  • Palaz F, Ozsoz M, Zarrinpar A, Sahin I. CRISPR in targeted therapy and adoptive T cell immunotherapy for hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2024.
  • Ozer M, Goksu SY, Akagunduz B, George A, Sahin I. Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials. Cancers, 2023.
  • Sahin I, Bilir B, Ali S, Sahin K, Kucuk O. Soy isoflavones in integrative oncology: increased efficacy and decreased toxicity of cancer therapy. Integrative Cancer Therapies, 2019.
  • Sahin I, Eturi A, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biology & Therapy, 2019.
  • Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. OncoTargets and Therapy, 2019.
  • Moschetta M, Mishima Y, Sahin I, et al. Role of endothelial progenitor cells in cancer progression. Biochimica et Biophysica Acta – Reviews on Cancer, 2014.
  • Koca E, …, Sahin I, …, Altundag K. Outcomes of locally advanced breast cancer patients with ≥10 positive axillary lymph nodes. Medical Oncology, 2013.
  • Kizilarslanoglu MC, …, Sahin I, Altundag K. Temozolomide-related infections: review of the literature. J BUON, 2011.

Follow for new translations and chapters: